The immunotherapy is now approved for people whose cancer has not progressed on platinum-based chemotherapy.

“Potentially practice-changing” data show patients with advanced urothelial carcinoma survive longer with immune-boosting drug after chemo.

More than half of patients treated with mitomycin experienced complete tumor remission.

Last year, the FDA approved three new antibody-drug conjugates for treating cancer.

Genitourinary Cancers Symposium reaches beyond the latest prostate, bladder and kidney cancer treatments.

Updated study results show antibody-drug conjugate plus Keytruda shrinks tumors in 73% of patients.

In a clinical trial, 46% of responding participants experienced a complete response lasting at least 12 months.